-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Breast cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C50.0–50.9) is a malignant tumor that originates in the breast tissue. Breast cancer cells begin inside the milk ducts of the breast. The earliest form (in situ) is not life-threatening and can be detected in early stages. The most common type of non-invasive (stage 0) types of breast cancer is called ductal carcinoma in situ (DCIS) (American Cancer Society, 2022; World Health Organization, 2024). DCIS refers to abnormal cells that...
-
Product Insights
NewLikelihood of Approval Analysis for Gram-Positive Bacterial Infections
Overview How likely is it that the drugs in Gram-Positive Bacterial Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gram-Positive Bacterial Infections Overview Gram-positive bacterial infections are caused by bacteria...
-
Product Insights
NewContinuous Positive Airway Pressure (CPAP) Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
A Continuous Positive Airway Pressure machine is used for the treatment of sleep apnea and in intensive care units as a form of ventilation. Continuous Positive Airway Pressure devices provide a gentle and unobstructed breathing by delivering a steady constant pressure of air through a hose which is connected to a nasal mask, nasal pillow or a full face mask. The mask must be carefully secured to the face so that no air escapes. This constant supply of air pressure...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebotelimab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebotelimab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebotelimab in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inavolisib in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inavolisib in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inavolisib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GQ-1001 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GQ-1001 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GQ-1001 in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FS-102 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-102 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-102 in...